Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Exelixis
ImmunityBio, Inc.
University of Pittsburgh
Mayo Clinic
University of Pittsburgh
7 Hills Pharma, LLC
Incyte Corporation
Bristol-Myers Squibb
Sarcoma Oncology Research Center, LLC
Children's National Research Institute
Molecular Templates, Inc.
Tempest Therapeutics
Fate Therapeutics
Jules Bordet Institute
Incyte Corporation
Apollomics (Australia) Pty. Ltd.